Development of Treatment Algorithm for Eradication of Helicobacter Pylori Based on Antibiotic Susceptibility Test
Not Applicable
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Drug: eradication of Helicobacter pylori
- Registration Number
- NCT02759029
- Lead Sponsor
- Gangnam Severance Hospital
- Brief Summary
Helicobacter pylori eradication (H. pylori) rates with clarithromycin-based triple therapy are declining, and an alternative strategy is needed urgently. The investigators sought to compare the efficacy of pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy vs. concomitant therapy for H. pylori eradication in a region with high rates of multiple drug resistance.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 123
Inclusion Criteria
- positive results of rapid urease test
Exclusion Criteria
- liver cirrhosis,
- chronic kidney disease,
- bleeding tendency,
- pregnant,
- allergy to antibiotics
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Susceptibility-guided group eradication of Helicobacter pylori Drugs according to antimicrobial susceptibility-guided treatment triple therapy group eradication of Helicobacter pylori Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk concomitant therapy group eradication of Helicobacter pylori Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk
- Primary Outcome Measures
Name Time Method eradication rate of Helicobacter pylori the H. pylori status was checked 4 weeks aft er the end of treatment using the 13 C-urea breath test.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Gangnam Severance Hospital
🇰🇷Seoul, Korea, Republic of